Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351891 | 1.00 | MDM4 (0.48) | MDM4TP53CTSSCTSKEPHX2 | |
| SCHEMBL1957887 | 1.00 | MDM4 (0.48) | MDM4TP53CTSSCTSKEPHX2 | |
| SCHEMBL28741504 | 0.93 | MDM4 (0.52) | MDM4TP53CTSSCTSKMDM2 | |
| SCHEMBL28741502 | 0.93 | MDM4 (0.52) | MDM4TP53CTSSCTSKMDM2 | |
| SCHEMBL29633851 | 0.92 | MDM2 (0.48) | MDM4TP53KMT2APTPN1MDM2 | |
| SCHEMBL12568250 | 0.92 | CTSS (0.52) | MDM4TP53CTSSCTSKPTPN1 | |
| SCHEMBL12568249 | 0.92 | CTSS (0.52) | MDM4TP53CTSSCTSKPTPN1 | |
| SCHEMBL2855134 | 0.91 | MDM4 (0.47) | MDM4TP53KMT2APTPN1MDM2 | |
| SCHEMBL2855137 | 0.91 | MDM4 (0.47) | MDM4TP53KMT2APTPN1MDM2 | |
| SCHEMBL21689062 | 0.91 | MDM4 (0.47) | MDM4TP53KMT2APTPN1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102702327-B | Solid-liquid phase synthesis method for alarelin acetate | GL BIOCHEM SHANGHAI CO LTD | 2013-10-30 | — | — | CN | claimed |
| CN-102702327-A | Solid-liquid phase synthesis method for alarelin acetate | GL BIOCHEM SHANGHAI CO LTD | 2012-10-03 | — | — | CN | claimed |
| EP-2917218-B1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2917218-B1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20140135270-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-15 | — | — | US | disclosed |
| WO-2014074658-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20110086847-A1 | THIADIAZOLE MODULATORS OF BETA ADRENERGIC RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-6423689-B1 | Peptidyl calcium channel blockers | WARNER-LAMBERT COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6153375-A | MAKING COMBINATORIAL LIBRARIES BY USING SPECIFIC SOLID SUPPORT AND THEN REPEATEDLY ADDING REAGENT, RECORDING IDENTIFY OF ZONES, AND SUBDIVIDING BATCHES | CAMBRIDGE COMBINATORIAL LIMITED (GB) | 2000-11-28 | — | — | US | disclosed |
| EP-0792280-A1 | METHOD OF MAKING A LIBRARY OF COMPOUNDS | Cambridge Combinatorial Ltd. (GB) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996016078-A1 | METHOD OF MAKING A LIBRARY OF COMPOUNDS | PFIZER LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086847-A1 | THIADIAZOLE MODULATORS OF BETA ADRENERGIC RECEPTOR | ADRB3, ADRB2, ADRB1 | MDM4 4800/4885TP53 4862/4885CTSS 4333/4885 |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | MDM4 4420/4885TP53 1521/4885CTSS 1088/4885 |
| US-20140135270-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BAX, API5, BCL2 | MDM4 894/4885TP53 34/4885CTSS 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.